• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用 C-蛋氨酸 PET-CT 与 MRI 融合成像在泌乳素瘤手术中进行功能成像,以实现更先进的手术规划和决策。

Implementation of functional imaging using C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery.

机构信息

Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Pituitary. 2022 Aug;25(4):587-601. doi: 10.1007/s11102-022-01230-2. Epub 2022 May 26.

DOI:10.1007/s11102-022-01230-2
PMID:35616762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9345807/
Abstract

PURPOSE

To report the first experience of our multidisciplinary team with functional imaging using C-methionine positron emission tomography-computed tomography (C-methionine PET-CT) co-registered with MRI (Met-PET/MRI) in clinical decision making and surgical planning of patients with difficult to treat prolactinoma.

METHODS

In eighteen patients with prolactinoma, referred to our tertiary referral centre because of intolerance or resistance for dopamine agonists (DA), Met-PET/MRI was used to aid decision-making regarding therapy.

RESULTS

Met-PET/MRI was positive in 94% of the patients. MRI and Met-PET/MRI findings were completely concordant in five patients, partially concordant in nine patients, and non-concordant in four patients. In five patients Met-PET/MRI identified lesion(s) that were retrospectively also visible on MRI. Met-PET/MRI was false negative in one patient, with a cystic adenoma on conventional MRI. Thirteen patients underwent transsphenoidal surgery, with nine achieving full biochemical remission, two clinical improvement and near normalized prolactin levels, and one patient clinical improvement with significant tumour reduction. Hence, nearly all patients (94%) were considered to have a positive outcome. Permanent complication rate was low. Three patients continued DA, two patients have a wait and scan policy.

CONCLUSION

Met-PET/MRI can provide additional information to guide multidisciplinary preoperative and intraoperative decision making in selected cases of prolactinoma. This approach resulted in a high remission rate with a low rate of complications in our expert centre.

摘要

目的

报告我们的多学科团队在使用 C-蛋氨酸正电子发射断层扫描-计算机断层扫描(C-蛋氨酸 PET-CT)与磁共振成像(Met-PET/MRI)融合的功能成像在治疗困难性泌乳素瘤患者的临床决策和手术计划中的首次经验。

方法

在 18 例因多巴胺激动剂(DA)不耐受或耐药而转诊至我们的三级转诊中心的泌乳素瘤患者中,使用 Met-PET/MRI 来辅助治疗决策。

结果

Met-PET/MRI 在 94%的患者中呈阳性。MRI 和 Met-PET/MRI 检查结果在 5 例患者中完全一致,在 9 例患者中部分一致,在 4 例患者中不一致。在 5 例患者中,Met-PET/MRI 识别出了回顾性可见的 MRI 病变。在 1 例患者中,Met-PET/MRI 为假阴性,MRI 显示为囊性腺瘤。13 例患者接受了经蝶窦手术,其中 9 例达到了完全生化缓解,2 例临床改善且泌乳素水平接近正常,1 例患者临床改善且肿瘤显著缩小。因此,几乎所有患者(94%)都被认为有积极的结果。永久性并发症发生率较低。3 例患者继续使用 DA,2 例患者采用等待和扫描策略。

结论

Met-PET/MRI 可以提供额外的信息,以指导选择病例的泌乳素瘤的多学科术前和术中决策。在我们的专家中心,这种方法导致了高缓解率和低并发症率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/2dd620d4e6e1/11102_2022_1230_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/07218688eaa9/11102_2022_1230_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/1f43bd73ea8f/11102_2022_1230_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/54d96c98d0b3/11102_2022_1230_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/667b734e54cc/11102_2022_1230_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/c730f544fabe/11102_2022_1230_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/2dd620d4e6e1/11102_2022_1230_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/07218688eaa9/11102_2022_1230_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/1f43bd73ea8f/11102_2022_1230_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/54d96c98d0b3/11102_2022_1230_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/667b734e54cc/11102_2022_1230_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/c730f544fabe/11102_2022_1230_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fc9/9345807/2dd620d4e6e1/11102_2022_1230_Fig6_HTML.jpg

相似文献

1
Implementation of functional imaging using C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery.采用 C-蛋氨酸 PET-CT 与 MRI 融合成像在泌乳素瘤手术中进行功能成像,以实现更先进的手术规划和决策。
Pituitary. 2022 Aug;25(4):587-601. doi: 10.1007/s11102-022-01230-2. Epub 2022 May 26.
2
C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy.C-蛋氨酸 PET 有助于定位对多巴胺激动剂治疗不耐受或抵抗的患者中的微泌乳素瘤。
Pituitary. 2022 Aug;25(4):573-586. doi: 10.1007/s11102-022-01229-9. Epub 2022 May 24.
3
F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly.F-氟乙基酪氨酸 PET 与 MRI 共配准在持续肢端肥大症患者中的应用。
Clin Endocrinol (Oxf). 2024 Aug;101(2):142-152. doi: 10.1111/cen.15079. Epub 2024 May 31.
4
Clinical use of [F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.氟代乙基-L-酪氨酸 PET 与 MRI 同机融合显像在泌乳素瘤术后残余灶定位中的临床应用。
Pituitary. 2024 Oct;27(5):614-624. doi: 10.1007/s11102-024-01430-y. Epub 2024 Jul 23.
5
Clinical application of combination [C]C-methionine and [N]N-ammonia PET/CT in recurrent functional pituitary adenomas with negative MRI or [F]F-FDG PET/CT.[C]碳-蛋氨酸和[N]氮-氨PET/CT联合应用于MRI或[F]氟-脱氧葡萄糖PET/CT检查结果为阴性的复发性功能性垂体腺瘤的临床应用
BMC Endocr Disord. 2024 Feb 5;24(1):19. doi: 10.1186/s12902-024-01543-2.
6
Utility of 11C-Methionine and 18F-FDG PET/CT in Patients With Functioning Pituitary Adenomas.11C-蛋氨酸和 18F-FDG PET/CT 在功能性垂体腺瘤患者中的应用价值。
Clin Nucl Med. 2016 Mar;41(3):e130-4. doi: 10.1097/RLU.0000000000001085.
7
18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.18F-FDOPA 摄取反映了多巴胺激动剂治疗垂体催乳素瘤的疗效。
Clin Nucl Med. 2018 Sep;43(9):e324-e325. doi: 10.1097/RLU.0000000000002202.
8
Utility of N-Ammonia PET/CT to Detect Pituitary Tissue in Patients with Pituitary Adenomas.N-氨质子 PET/CT 检测垂体腺瘤患者垂体组织的应用。
Acad Radiol. 2019 Sep;26(9):1222-1228. doi: 10.1016/j.acra.2018.09.015. Epub 2018 Oct 12.
9
11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas.11C-蛋氨酸PET用于复发性垂体腺瘤的诊断与管理。
Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):169-78. doi: 10.1007/s00259-005-1882-0. Epub 2005 Oct 15.
10
Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings.基于 11C-蛋氨酸 PET 在 MRI 结果不明确的复发性库欣病中的临床决策。
J Neurosurg. 2023 Jun 30;139(6):1671-1680. doi: 10.3171/2023.5.JNS23179. Print 2023 Dec 1.

引用本文的文献

1
Multimodal Model for Non-Invasive Detection of DRD2, SSTR2 and ESR1 Receptor Profiling in Pituitary Neuroendocrine Tumors: A Retrospective Study.垂体神经内分泌肿瘤中DRD2、SSTR2和ESR1受体谱无创检测的多模态模型:一项回顾性研究
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251353305. doi: 10.1177/15330338251353305. Epub 2025 Jun 23.
2
The Changing Treatment Paradigm for Prolactinoma-A Prospective Series of 100 Consecutive Neurosurgical Cases.泌乳素瘤治疗模式的转变——100例连续神经外科病例的前瞻性系列研究
J Clin Endocrinol Metab. 2025 May 19;110(6):e1833-e1844. doi: 10.1210/clinem/dgae652.
3
Clinical use of [F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.

本文引用的文献

1
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.意大利临床内分泌学家协会(AME)和临床内分泌学国际分会(ICCE)。临床实践立场声明:催乳素分泌肿瘤。
Eur J Endocrinol. 2022 Feb 3;186(3):P1-P33. doi: 10.1530/EJE-21-0977.
2
Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience.非侵袭性催乳素垂体瘤术后缓解:单中心经验。
Ann Endocrinol (Paris). 2022 Feb;83(1):1-8. doi: 10.1016/j.ando.2021.11.008. Epub 2021 Dec 3.
3
Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study.
氟代乙基-L-酪氨酸 PET 与 MRI 同机融合显像在泌乳素瘤术后残余灶定位中的临床应用。
Pituitary. 2024 Oct;27(5):614-624. doi: 10.1007/s11102-024-01430-y. Epub 2024 Jul 23.
4
EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours.欧洲核医学协会关于正电子发射断层扫描在疑似功能性垂体神经内分泌肿瘤中的立场
Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2367-2370. doi: 10.1007/s00259-024-06728-4.
5
Multidisciplinary Team Care in Pituitary Tumours.垂体肿瘤的多学科团队护理
Cancers (Basel). 2024 Feb 27;16(5):950. doi: 10.3390/cancers16050950.
6
Consecutive resections of double pituitary adenoma for resolution of Cushing disease: illustrative case.连续切除双垂体腺瘤以治愈库欣病:病例说明
J Neurosurg Case Lessons. 2023 Nov 27;6(22). doi: 10.3171/CASE23485.
7
Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?泌乳素瘤手术治疗患者的治疗轨迹:他们为何选择手术?
Pituitary. 2023 Oct;26(5):611-621. doi: 10.1007/s11102-023-01346-z. Epub 2023 Sep 10.
8
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.催乳素分泌型垂体腺瘤的诊断和治疗:垂体学会国际共识声明。
Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5.
9
The utility of PET for detecting corticotropinomas in Cushing disease: a scoping review.PET 在库欣病中检测促肾上腺皮质激素瘤的效用:范围综述。
Neurosurg Rev. 2023 Jul 1;46(1):160. doi: 10.1007/s10143-023-02077-2.
10
Recent advances in understanding and managing pituitary adenomas.垂体腺瘤的认识与管理的最新进展
Fac Rev. 2023 Mar 21;12:6. doi: 10.12703/r/12-6. eCollection 2023.
垂体瘤切除术替代多巴胺激动剂治疗微泌乳素瘤:一项队列研究。
Eur J Endocrinol. 2021 Oct 21;185(6):783-791. doi: 10.1530/EJE-21-0293.
4
Surgery and Medical Treatment in Microprolactinoma: A Systematic Review and Meta-Analysis.微泌乳素瘤的手术与药物治疗:一项系统评价与荟萃分析
Int J Endocrinol. 2021 Aug 30;2021:9930059. doi: 10.1155/2021/9930059. eCollection 2021.
5
Cure and Hormonal Control After Prolactinoma Resection: Case Series and Systematic Review.催乳素瘤切除术后的治愈与激素控制:病例系列及系统评价
J Endocr Soc. 2021 Apr 28;5(10):bvab074. doi: 10.1210/jendso/bvab074. eCollection 2021 Oct 1.
6
Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.经多巴胺激动剂治疗抵抗的泌乳素瘤经蝶窦手术治疗的结果:一项回顾性研究。
Hormones (Athens). 2021 Dec;20(4):745-752. doi: 10.1007/s42000-021-00309-y. Epub 2021 Jul 18.
7
Treatment of hyperprolactinemia: A single-institute experience.高泌乳素血症的治疗:单中心经验。
J Chin Med Assoc. 2021 Nov 1;84(11):1019-1022. doi: 10.1097/JCMA.0000000000000584.
8
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors.重新评估经蝶窦手术在泌乳素分泌型垂体瘤中的作用
Cancers (Basel). 2021 Jun 29;13(13):3252. doi: 10.3390/cancers13133252.
9
Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term.原发性药物或手术治疗对催乳素瘤患者长期体重指数和代谢状况的影响。
J Clin Transl Endocrinol. 2021 Jun 17;24:100258. doi: 10.1016/j.jcte.2021.100258. eCollection 2021 Mar.
10
Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.手术是侵袭性泌乳素瘤的安全、有效的一线治疗方式。
Pituitary. 2021 Dec;24(6):955-963. doi: 10.1007/s11102-021-01168-x. Epub 2021 Jun 29.